Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20639110 | 0.90 | MAPT (0.56) | MEN1KMT2ASMN1; SMN2GPR27AURKA | |
| SCHEMBL20644023 | 0.82 | SCN8A (0.66) | — | |
| SCHEMBL16397874 | 0.81 | CA1 (0.57) | — | |
| SCHEMBL20638776 | 0.81 | MAPT (0.56) | MEN1KMT2ASMN1; SMN2AURKAKCNK3 | |
| SCHEMBL20644180 | 0.80 | SCN8A (0.69) | — | |
| SCHEMBL27654215 | 0.79 | MEN1 (0.74) | MEN1KMT2ASMN1; SMN2PARP1PARP10 | |
| SCHEMBL20644020 | 0.78 | SCN8A (0.68) | — | |
| SCHEMBL20644016 | 0.76 | SCN8A (0.56) | — | |
| SCHEMBL20639239 | 0.76 | PARP1 (0.50) | MEN1KMT2ASMN1; SMN2GPR27KCNK3 | |
| SCHEMBL15901645 | 0.75 | SCN10A (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| EP-3651752-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111065383-A | Carboxamides useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | MEN1 3203/4885KMT2A 1313/4885SMN1; SMN2 349/4885 |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | MEN1 3203/4885KMT2A 1313/4885SMN1; SMN2 349/4885 |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | MEN1 3203/4885KMT2A 1313/4885SMN1; SMN2 349/4885 |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | MEN1 3203/4885KMT2A 1313/4885SMN1; SMN2 349/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | MEN1 3203/4885KMT2A 1313/4885SMN1; SMN2 349/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | MEN1 3203/4885KMT2A 1313/4885SMN1; SMN2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.